The stock's fall snapped a two-day winning streak.

On CNBC's “Halftime Report Final Trades,” Stephen L. Weiss of Short Hills Capital Partners recommended buying TransDigm Group ...

This was the stock's second consecutive day of gains.

AbbVie Inc.’s TV advertisements featuring tennis legend Serena Williams make misleading claims about the effectiveness of its ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

The FDA has scolded AbbVie for making false and misleading claims about a TV ad about a migraine pill that features Serena ...

Just a few short weeks after winning an FDA Fast Track tag for its investigational BTK degrader in certain blood cancers, ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $196.42 which represents a slight increase of $3.02 or 1.56% from the prior close of $193.4. The stock opened at $194.97 and touched a ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $192.86 which represents a decrease of $-4.15 or -2.11% from the prior close of $197.01. The stock opened at $196.96 and touched a low of $192.

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...